Exposure to vesicants, including sulfur mustard and nitrogen mustard, causes damage to the epithelia of the respiratory tract and the lung. With time, this progresses to chronic disease, most notably, pulmonary fibrosis. The pathogenic process involves persistent inflammation and the release of cytotoxic oxidants, cytokines, chemokines, and profibrotic growth factors, which leads to the collapse of

Achalasia is a primary motility disorder of the esophagus, and while there are several treatment options, there is no consensus regarding them. When therapeutic intervention for achalasia fails, a careful evaluation of the cause of the persistent or recurrent symptoms using upper endoscopy, esophageal manometry, and contrast radiologic studies is required to understand the cause of therapy failure

An aspirational global food system is one that delivers across a suite of the Sustainable Development Goals (SDGs), including universal access to healthy diets, which can also codeliver on climate and environment SDGs. The literature has downplayed the relative contribution of dietary change to sustainable food systems. In this perspective article, we argue that the potential for positive transformational

Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), an aggressive cancer with a poor prognosis. Our understanding of the pathogenesis and Barrett's metaplasia is incomplete, and this has limited the development of new therapeutic targets and agents, risk stratification ability, and management strategies. This review outlines current insights into the biology of

Until now, neoadjuvant therapy plus surgical resection of the primary tumor and potential metastatic lymph nodes (LNs) has been the current optimal treatment for locally advanced thoracic esophageal cancer (EC). LN metastasis is one of the most negative prognostic factors for thoracic esophageal squamous cell carcinoma (ESCC). However, the extent of LN dissection for thoracic ESCC has long been controversial

Impedance has traditionally been employed in esophageal disease as a means to assess bolus flow and reflux episodes. Recent and ongoing research has provided new and novel applications for this technology. Measurement of esophageal mucosal impedance, via either multichannel intraluminal impedance catheters or specially designed endoscopically deployed impedance catheters, provides a marker of mucosal

Einstein famously claimed that “the most incomprehensible thing about the universe is that it is comprehensible.” This statement suggests that no amount of scientific explanation will suffice to make sense of the bizarre situation of the human mind within the universe. So what are the actual roles of awe and wonder within the framework of contemporary science? How, for instance, do awe and wonder inform

Awe and wonder appear to be powerful emotions that can inform and shape our attitudes toward ourselves and others, especially in relation to the larger meaning and purpose of our lives. What are the psychological underpinnings of these universal emotions? How does awe, for example, relate to self‐knowledge, and more generally to understanding the enigmatic contradictions of human nature? Is it possible

From the macrocosm of the universe to the microcosm of the human body, our discoveries about ourselves and the natural world continue to spark our experience of awe and wonder . But how exactly does science define and explain the experience of awe and wonder? Social psychologist Michelle Shiota, writer Caspar Henderson, and astrophysicist Alex Filippenko unpack the emerging science behind the emotions

Tendinopathy is a common musculoskeletal disorder characterized by chronic low‐grade inflammation and tissue degeneration. Tendons have poor innate healing ability and there is currently no cure for tendinopathy. Studies elucidating mechanisms underlying the pathogenesis of tendinopathy and mechanisms mediating the genesis of tendons during development have provided novel targets and strategies to

For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid‐targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease‐modifying agents. It is becoming more apparent that